NAA50-mediated SLU7 stabilization promotes cisplatin resistance in bladder cancer via regulating MAP3K3 mRNA nuclear export and p38 MAPK activation Authors: Benlin Wang, Xianchong Zheng, Qingsheng Hua, Feng Zou, Tao Huang, Jiawei Chen Published: 2026 ABSTRACT BackgroundCisplatin-based chemotherapy is first-line for muscle-invasive bladder cancer (BLCA), but chemoresistance remains the primary barrier to clinical efficacy. RNA-binding proteins (RBPs) orchestrate post-transcriptional gene regulation and are increasingly implicated in cancer chemoresistance; however, the role and regulatory mechanism of the splicing factor RBP SLU7 in BLCA cisplatin resistance remain completely unknown.MethodsWe analyzed SLU7 expression and clinical prognosis in two independent cisplatin-treated BLCA cohorts (GSE87304, GSE169455). Cisplatin-resistant BLCA cell lines (T24-CIS, UMUC3-CIS) were established for functional assays (CCK-8, qRT-PCR, western blotting). Molecular interactions were validated by RIP-qPCR, immunofluorescence(IF), RNA-FISH, nucleocytoplasmic fractionation, co-immunoprecipitation (co-IP), and mass spectrometry (MS). In vivo therapeutic efficacy was assessed in BLCA xenograft models.ResultsSLU7 was significantly upregulated in cisplatin-resistant BLCA cells, and high SLU7 expression independently predicted poor cancer-specific survival (CSS) and recurrence-free survival (RFS) in cisplatin-treated patients. SLU7 knockdown suppressed MAP3K3 expression, inhibited p38 MAPK pathway, and restored cisplatin sensitivity. Mechanistically, SLU7 directly bound MAP3K3 mRNA and promoted its nuclear export—a non-canonical function independent of its canonical splicing activity. MS and Co-IP identified NAA50 as the upstream regulator that catalyzes N-terminal acetylation of SLU7 to prevent its ubiquitin-proteasomal degradation, thereby sustaining SLU7 stability. Pharmacological inhibition of NAA50 with Naa50-IN-1 destabilized SLU7, blocked the MAP3K3-p38 axis, and reversed cisplatin resistance in vitro and in vivo.ConclusionsWe uncover a novel NAA50–SLU7–MAP3K3-p38 MAPK regulatory axis that drives cisplatin resistance in BLCA. NAA50-mediated N-terminal acetylation stabilizes SLU7, which in turn facilitates MAP3K3 mRNA nuclear export to activate p38 MAPK signaling. Targeting NAA50 represents a promising therapeutic strategy to overcome cisplatin resistance in BLCA, and SLU7 serves as a predictive biomarker for cisplatin response.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13402-026-01219-0. Introduction Bladder cancer (BLCA) is one of the most prevalent urological malignancies worldwide. Muscle-invasive bladder cancer (MIBC) accounts for over 70% of BLCA-related mortality due to its high invasiveness, frequent recurrence, and distant metastasis [1, 2]. Cisplatin-based chemotherapy, as the cornerstone of neoadjuvant, adjuvant, and palliative treatment for MIBC, has significantly improved clinical outcomes over the past decades [3]. However, the acquisition of cisplatin resistance—either de novo or acquired during treatment—occurs in over 40% of patients, leading to treatment failure, disease progression, and a dismal 5-year survival rate of less than 50% [4, 5]. Despite extensive research, the molecular mechanisms underlying cisplatin resistance in BLCA remain incompletely elucidated, and there is a critical lack of targeted strategies to overcome this barrier. This knowledge gap highlights an urgent need to identify novel regulatory networks driving cisplatin resistance and to translate these findings into actionable therapeutic targets. Post-transcriptional regulation has emerged as a key determinant of cancer progression and chemoresistance, with RNA-binding proteins (RBPs) serving as central orchestrators of this process [6, 7]. RBPs modulate nearly every step of mRNA metabolism, including splicing, stability, subcellular localization, and translation, thereby fine-tuning the expression of oncogenic or tumor-suppressive programs in a context-dependent manner [8, 9]. Accumulating evidence indicates that dysregulated RBPs contribute to cisplatin resistance by rewiring cellular responses to DNA damage, altering drug efflux/influx, or activating pro-survival signaling pathways [10]. For instance, IGF2BP3 mediates m6A-dependent stabilization of TMA7 mRNA to promote cisplatin resistance in laryngeal cancer [11], while NAT10 enhances ac4C-associated DNA repair to drive chemoresistance in BLCA [12]. However, the landscape of RBPs involved in BLCA cisplatin resistance is far from complete, and the non-canonical functions of many well-characterized RBPs remain unexplored. Synergistic lethal with U5 snRNA 7 (SLU7) was initially identified as a core component of the spliceosome, playing an essential role in pre-mRNA alternative splicing and genome integrity maintenance [13, 14]. Emerging studies have uncovered pleiotropic roles of SLU7 in tumorigenesis, with its function varying across cancer types: it promotes proliferation in triple-negative breast cancer [15], exerts tumor-promoting effects in liver cancer precancerous lesions [16], and facilitates immune escape in BLCA by activating the PI3K/Akt pathway [17]. Notably, SLU7’s ability to interact with mRNA and regulate post-transcriptional processes extends beyond its classical splicing function [18]—our previous work demonstrated that SLU7 forms a ribonucleoprotein complex to enhance the translation of class IA PI3K mRNA [17]. Given its multifaceted roles in RNA metabolism and cancer biology, we hypothesized that SLU7 might exert unrecognized functions in mediating cisplatin resistance in BLCA. However, to date, the role of SLU7 in chemoresistance, particularly cisplatin resistance, has not been investigated in any cancer type, representing a critical gap in our understanding of both SLU7 biology and BLCA therapeutic resistance. In this study, we aimed to address this knowledge gap by systematically investigating the functional role and molecular mechanism of SLU7 in cisplatin resistance of BLCA. We further sought to identify upstream regulators of SLU7 and validate the therapeutic potential of targeting this regulatory axis. Our findings uncover a novel “NAA50–SLU7–MAP3K3-p38 MAPK” signaling pathway that drives cisplatin resistance, highlighting SLU7 as a key mediator of chemoresistance and NAA50 as a promising therapeutic target for reversing cisplatin resistance in BLCA. This work not only expands our understanding of the non-canonical functions of SLU7 but also provides a rationale for developing combination therapies to improve the efficacy of cisplatin-based chemotherapy in BLCA patients. Methods and materials Clinical data analysis Clinical follow-up data and gene expression data from two cisplatin-treated BLCA cohorts (GSE87304 and GSE169455) were analyzed to evaluate the association between SLU7 expression and cisplatin response, as well as patient prognosis. Data were normalized using the robust multi-array average (RMA) method, including background correction, quantile normalization and probe summarization; batch effects between different experimental batches were further corrected with the ComBat algorithm (sva R package). The optimal cut-off value for SLU7 expression grouping was pre-specified and determined by the max-rank statistics method (surv_cutpoint, survminer R package) to avoid subjective grouping bias. Kaplan-Meier survival curves were plotted and the log-rank test was used for significance analysis. Multivariable Cox regression proportional hazards regression models were constructed to validate the independent prognostic value of SLU7. For screening of MAP3K family members associated with SLU7 and cisplatin resistance, differential expression and correlation analyses were performed for all family genes, and the Benjamini-Hochberg (BH) method was applied for multiple testing correction to control the false discovery rate (FDR), with the screening criteria set as |log2FC| >0.5 and adjusted p-value < 0.05. All bioinformatics analyses were conducted using R software (version 4.3.3). Cell culture and establishment of cisplatin-resistant BLCA cells Human BLCA cell lines (T24 and UMUC3) and HEK293T cells were obtained from the American Type Culture Collection (Manassas, USA) and authenticated by short tandem repeat profiling. T24 and HEK293T cells were cultured in Dulbecco’s modified Eagle medium (DMEM, Invitrogen, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. UMUC3 cells were maintained in minimum essential medium (MEM, Invitrogen, USA) containing nonessential amino acids, 10% FBS, and 1% penicillin/streptomycin. All cells were incubated at 37 °C under 5% CO₂ and tested negative for mycoplasma contamination. Cisplatin-resistant cell lines (T24-CIS and UMUC3-CIS) were established by continuous exposure of parental cells to progressively increasing concentrations of cisplatin (2.5 to 10 μM; APExBIO, USA) over 3–5 months. Briefly, cells were treated with cisplatin at 60% confluency, with the concentration gradually increased from 2.5 μM to 10 μM. After 24 h of exposure, the medium was discarded, and cells were rinsed with sterile saline and cultured in fresh medium. Resistant cells were maintained in medium containing 5 μM cisplatin to preserve the resistant phenotype. Pharmacological treatments Adezmapimod (HY-10256, a specific p38 MAPK inhibitor) was purchased from Beyotime (Shanghai, China) and used at a working concentration of 10 μM for cell treatment. Naa50-IN-1 (Compound 4a, a specific NAA50 inhibitor) was purchased from MedChemExpress (MCE, Shanghai, China) and used at a working concentration of 5 nM for in vitro functional inhibition experiments of NAA50. All pharmacological inhibitors used in this study were dissolved in dimethyl sulfoxide (DMSO) to prepare stock solutions and further diluted with complete culture medium to the required working concentrations for in vitro experiments; the final concentration of DMSO in all treatment groups was controlled at ≤0.1% to exclude non-specific solvent effects. Cell counting kit-8 (CCK-8) assay T24-CIS and UMUC3-CIS cells were seeded in 96-well plates at 5 × 103 cells/well and treated with cisplatin (0.1–40 μM for T24-CIS; 0.1–60 μM for UMUC3-CIS) for 48 h. After incubation with 10% CCK-8 solution (Vazyme, Nanjing, China) for 1 h, absorbance was measured at 450 nm using a microplate reader. The 50% inhibitory concentration (IC₅₀) was calculated with nonlinear regression analysis. RNA isolation and quantitative real-time polymerase chain reaction Total RNA was extracted using TRIzol reagent (Thermo Fisher Scientific, USA). cDNA synthesis was performed with HiScript II Q RT SuperMix (Vazyme, Nanjing, China), and qRT-PCR was conducted using SYBR Green Master Mix (Vazyme, Nanjing, China) on a CFX96 Touch system (Bio-Rad, USA). GAPDH was used as an internal control, and relative gene expression was calculated using the 2− ΔΔCT method. Primer sequences are listed in Supplementary Table S1. RNA-sequencing data analysis The RNA-seq was performed by Novogene Bioinformatics Technology Co., Ltd. To compare the transcriptomic profiles between SLU7-knockdown T24-CIS cells and parental T24-CIS cells. Qualified total RNA(≥1 μg) was used for standard mRNA-seq library construction, and sequencing was conducted on Illumina platform to generate 150 bp paired-end reads. Raw sequencing data were filtered to removed adapter-containing, low-quality and N-base reads for quality control; high-quality clean reads were aligned to the hg38 human reference genome using HISAT2. Gene expression levels were quantified as FPKM by featueCounts with hg38 corresponding GTF annotation files, and low-expression genes were filtered out to ensure analysis reliability. Differential expression analysis between groups was performed using DESeq2, with the BH method for FDR control; genes with adjusted p < 0.05 were defined as significantly differentially expressed. Gene Ontology (GO) enrichment analysis of differentially expressed genes was implemented using clusterProfiler with gene length bias correction, and terms with adjusted p < 0.05 were considered significantly enriched. Plasmid construction, siRNA transfection, and lentiviral transduction ShRNA sequences targeting SLU7, MAP3K3, PRPF8, and CWC22 were cloned into the PLKO.1 vector. Coding sequences of SLU7, MAP3K3, CWC22, PRPF8, and NAA50 with C-terminal Flag tags were inserted into the PSIN-EF1α-puro vector. Plasmid transfection was performed using Lipofectamine 8000 (Beyotime, Shanghai, China). SiRNAs targeting NAT family members were purchased from RiboBio (Guangzhou, China), and transfection was conducted with Lipofectamine 8000. For stable knockdown, T24-CIS and UMUC3-CIS cells were transduced with lentiviruses at a multiplicity of infection (MOI) of 30, followed by puromycin selection (0.75 μg/mL) for one week. ShRNA and siRNA sequences are provided in Supplementary Table S2. Nuclear/Cytoplasmic fractionation One million cells were incubated in 100 μL hypotonic buffer (10 mM Tris-HCl pH 7.4, 1.5 mM MgCl₂, 10 mM KCl, 1% NP-40) on ice for 10 min to separate intact nuclei from the cytoplasmic fraction. The nuclei were pelleted by centrifugation at 5,000 × g and 4 °C for 10 min, and the supernatant (cytoplasmic fraction) was collected. The nuclear pellet was washed once with 100 μL hypotonic buffer, re-centrifuged under the same conditions, and resuspended in 100 μL hypotonic buffer. Total RNA was isolated from both the cytoplasmic and nuclear fractions using TRIzol reagent. Generation and validation of the acetyl-SLU7-Ser2 antibody The site-specific polyclonal antibody against SLU7 acetylated at serine 2 (SLU7^S2ac) was generated by ABclonal using a synthetic acetylated serine-containing peptide as the immunogen. Antibodies were affinity-purified using the acetylated peptide antigen and validated by antigen-affinity purification and ELISA titer assay. Western blotting Cell lysis was performed on ice using RIPA buffer supplemented with protease and phosphatase inhibitors (Fdbio Science, Hangzhou, China). Lysates were centrifuged (14,000 × g, 4 °C, 20 min), and proteins were separated by 4–12% SDS-polyacrylamide gel electrophoresis (PAGE), transferred to PVDF membranes (Millipore, USA), and blocked with QuickBlock solution (Beyotime, Shanghai, China) for 10 min. Membranes were incubated with primary antibodies overnight at 4 °C, followed by horseradish peroxidase-conjugated secondary antibodies. Signals were visualized using enhanced chemiluminescence reagent. Primary antibodies were used against SLU7 (12050–1-1AP, Proteintech, 1:500), MAP3K3 (21072–1-AP, Proteintech, 1:500), p38 (9212, Cell Signaling Technology, 1:1,000), p-p38 (8690, Cell Signaling Technology, 1:1,000), JNK (9252, Cell Signaling Technology, 1:1,000), p-JNK (4668, Cell Signaling Technology, 1:1,000), ERK1/2 (5726, Cell Signaling Technology, 1:1,000), p-ERK1/2 (4695, Cell Signaling Technology, 1:1,000), ERK5 (4695, Cell Signaling Technology, 1:1,000), p-ERK5 (3371, Cell Signaling Technology, 1:1,000), Acetyl-SLU7-Ser2 (SLU7^S2ac, ABclonal, 1:500), PRPF8 (11171–1-AP, Proteintech, 1:1,000), CWC22 (26898–1-AP, Proteintech, 1:1,000), NAA50 (A4996, ABclonal, 1:1,000), Flag tag (8146, Cell Signaling Technology, 1:2,000), GAPDH (60004–1-Ig, Proteintech, 1:10,000). RNA immunoprecipitation (RIP) RIP was performed using the Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Sigma-Aldrich, Germany) following the manufacturer’s protocol. UMUC3 cells expressing SLU7-Flag, CWC22-Flag, or PRPF8-Flag were lysed with RIP lysis buffer supplemented with a protease inhibitor cocktail and RNase inhibitor. The cell lysates were then incubated overnight at 4 °C with Flag tag antibody (14793, Cell Signaling Technology) or normal rabbit IgG (as a negative control). After incubation with protein A/G magnetic beads for 2 h at 4 °C under gentle rotation, the immunoprecipitants were washed eight times with RIP wash buffer (supplemented with protease and RNase inhibitors). Total RNA was isolated from the purified immunoprecipitants using TRIzol reagent for subsequent qRT-PCR analysis. Immunofluorescence (IF) and single molecule inexpensive FISH (smiFISH) To confirm the co-localization between SLU7 and MAP3K3 mRNA, UMUC3 cells were seeded onto coverslips and cultured for 24 h before further experiments. For IF staining: cells were fixed with 4% paraformaldehyde for 15 min, followed by permeabilization with 0.5% Triton X-100 for 10 min. After blocking in blocking buffer at 37 °C for 1 h, cells were incubated overnight at 4 °C with a SLU7 primary antibody (sc-376985, Santa Cruz Biotechnology, 1:25). On the following day, cells were incubated with an Alexa Fluor 488-conjugated goat anti-mouse secondary antibody (A-21202, Thermo Fisher Scientific, 1:200) at 37 °C for 1 h. Subsequently, cells were washed with PBS and processed for smiFISH. Cy3-labeled FLAP probes and MAP3K3 primary probes were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). To assess the subcellular localization of MAP3K3 following SLU7 knockdown, T24-CIS and UMUC3-CIS cells were subjected to smiFISH. The smiFISH assay was performed as previously described [19], and probe sequences are provided in Supplementary Table S3. Immunoprecipitation (IP) and mass spectrometry (MS) For IP assays, cell lysates were prepared as described above for western blotting. Lysates were then incubated overnight at 4 °C under gentle rotation with Flag tag antibody (14793, Cell Signaling Technology), followed by incubation with protein A/G magnetic beads (88803, Thermo Fisher Scientific) for 2 h at 4 °C under gentle rotation. Subsequently, immunoprecipitants were washed eight times with RIPA buffer supplemented with protease inhibitors, and analyzed by western blotting or MS. For MS, the SLU7-Flag complex was immunoprecipitated with Flag tag antibody from UMUC3 cells expressing SLU7-Flag. Purified immunoprecipitants were resolved by gradient SDS-PAGE and subjected to MS. Briefly, gels were minced and destained with 50% acetonitrile in 50 mM ammonium bicarbonate. Proteins were reduced with 10 mM dithiothreitol at 56 °C, alkylated with 55 mM iodoacetamide at room temperature (RT) in the dark, and digested with trypsin at 37 °C for 20 h. Peptides were extracted with 1% trifluoroacetic acid in 50% acetonitrile, vacuum-dried, and reconstituted with 0.1% formic acid. Pretreated samples were analyzed by nanoscale liquid chromatography-tandem MS, with data acquired via data-dependent analysis and processed using PLGS software. Cycloheximide (CHX) chase assay UMUC3 cells in each group were treated with 10 μg/mL CHX (Aladdin, Shanghai, China) for 0, 2, 4, 6, and 8 h. SLU7 protein expression levels were determined by western blotting. Ubiquitination assay The 293T cells were treated with 10 μg/mL MG132 (Selleck, USA) for 12 h to inhibit proteasomal degradation prior to harvest. Cell lysates were prepared in RIPA lysis buffer supplemented with a protease inhibitor cocktail. The lysates were incubated overnight at 4 °C with gentle rotation with anti-Flag antibody and protein A/G magnetic beads. The immunoprecipitates were collected and washed thoroughly with RIPA buffer, and the ubiquitination level of Flag-tagged SLU7 was detected and analyzed by western blotting. Animals and in vivo experiments Female nude mice (6–8 weeks old, 19.2 ± 2.1 g) were purchased from SPF Biotechnology Co., Ltd (Beijing, China) and housed under specific pathogen-free (SPF) conditions (24 ± 1 °C, 50 ± 10% relative humidity, 12 h light/dark cycle) with free access to food and water. Mice were acclimatized for 5 days prior to experimental manipulation to ensure physiological stability. For in vivo tumorigenicity assays, 5 × 106 T24-CIS cells suspended in 100 μL PBS were subcutaneously injected into the posterior flanks of mice. Mice were randomly divided into four groups (n = 6 per group) as follows: DMSO + PBS, Naa50-IN-1 + PBS, DMSO + cisplatin, and Naa50-IN-1 + cisplatin. Both compounds were administered via weekly intraperitoneal injection. Naa50-IN-1 was dosed at 2 mg/kg once weekly, while cisplatin was administered at 5 mg/kg once weekly. Tumor volume was measured every 3 days, and tumor volume was calculated using the formula: tumor volume = 0.52 × length × width2. Mice were euthanized when tumor volume reached ~1500 mm3, and tumors were excised, weighed, and photographed. All animal experiments were approved by the Institutional Animal Care and Use Committee of the Eighth Affiliated Hospital, Southern Medical University (approval number: SDYY-HT-12–2407-001). Statistical analysis All statistical analyses were conducted using GraphPad Prism software (version 10.0.0). All quantitative data are presented as mean ± standard deviation (SD) from three independent experiments. The Chi-square test or Fisher’s exact test was employed to compare differences between categorical variables. Statistical significance was evaluated using two-tailed Student’s t-test for two-group comparisons, and one-way or two-way analysis of variance (ANOVA) for multiple-group comparisons. A p-value < 0.05 was considered statistically significant. Significance levels were marked as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns indicates no significant difference. Results SLU7 upregulation in cisplatin-resistant BLCA correlates with poor clinical prognosis and drives cisplatin resistance To address the unmet need of identifying novel RBPs that mediate cisplatin resistance in BLCA, we first analyzed SLU7 expression and its correlation with clinical outcomes in two independent cisplatin-treated BLCA cohorts (GSE169455 and GSE87304). In the GSE169455 cohort, high SLU7 expression was significantly associated with shorter cancer-specific survival (CSS; HR = 1.89, 95% CI: 1.01–3.55) and showed a trend toward shorter recurrence-free survival (RFS; HR = 1.64, 95% CI: 0.92–2.91). In the GSE87304 cohort, high SLU7 expression was clearly associated with shorter recurrence-free survival (RFS, HR = 2.29, 95% CI: 1.19–4.41). Kaplan-Meier survival analysis confirmed these results (Figs. 1A–C), indicating SLU7 as a potential prognostic biomarker for cisplatin response.Fig. 1SLU7 knockdown enhances cisplatin sensitivity in cisplatin-resistant BLCA cells. (A) Kaplan-Meier analysis of cancer-specific survival (CSS) in BLCA patients from the GSE169455 cohort stratified by SLU7 expression. (B) Kaplan-Meier analysis of recurrence-free survival (RFS) in BLCA patients from the GSE169455 cohort stratified by SLU7 expression. (C) Kaplan-Meier analysis of RFS in BLCA patients from the GSE87304 cohort stratified by SLU7 expression. (D) Western blotting analysis of SLU7 protein expression in parental BLCA cells (T24-WT, UMUC3-WT) and their cisplatin-resistant derivatives (T24-CIS, UMUC3-CIS). (E) Western blotting validation of SLU7 knockdown in T24-CIS and UMUC3-CIS cells. (F) Western blotting validation of SLU7 overexpression in T24 and UMUC3 cells. (G-J) CCK-8 assays showing cisplatin IC₅₀ values in T24-CIS and UMUC3-CIS cells transfected with shSLU7#2/4 (G-H) and SLU7-Flag-transfected T24 and UMUC3 cells (I-J). Data are presented as mean ± SD. p-values were calculated using unpaired two-tailed Student’s t-test or one-way ANOVA. *p < 0.05, ***p < 0.001, ****p < 0.0001 SLU7 knockdown enhances cisplatin sensitivity in cisplatin-resistant BLCA cells. (A) Kaplan-Meier analysis of cancer-specific survival (CSS) in BLCA patients from the GSE169455 cohort stratified by SLU7 expression. (B) Kaplan-Meier analysis of recurrence-free survival (RFS) in BLCA patients from the GSE169455 cohort stratified by SLU7 expression. (C) Kaplan-Meier analysis of RFS in BLCA patients from the GSE87304 cohort stratified by SLU7 expression. (D) Western blotting analysis of SLU7 protein expression in parental BLCA cells (T24-WT, UMUC3-WT) and their cisplatin-resistant derivatives (T24-CIS, UMUC3-CIS). (E) Western blotting validation of SLU7 knockdown in T24-CIS and UMUC3-CIS cells. (F) Western blotting validation of SLU7 overexpression in T24 and UMUC3 cells. (G-J) CCK-8 assays showing cisplatin IC₅₀ values in T24-CIS and UMUC3-CIS cells transfected with shSLU7#2/4 (G-H) and SLU7-Flag-transfected T24 and UMUC3 cells (I-J). Data are presented as mean ± SD. p-values were calculated using unpaired two-tailed Student’s t-test or one-way ANOVA. *p < 0.05, ***p < 0.001, ****p < 0.0001 To validate the clinical observation, we established cisplatin-resistant BLCA cell lines (T24-CIS and UMUC3-CIS) via long-term stepwise cisplatin induction. These resistant cells exhibited significantly higher IC₅₀ values for cisplatin compared to parental wild-type (WT) cells (Supplementary Figures 1A and 1B). Western blotting confirmed that SLU7 protein expression was markedly elevated in T24-CIS and UMUC3-CIS cells relative to their WT counterparts (Fig. 1D), consistent with the clinical cohort data. To elucidate the functional role of SLU7 in cisplatin resistance, we performed gain- and loss-of-function experiments in multiple BLCA cell models. We confirmed the knockdown efficiency of SLU7 in T24-CIS and UMUC3-CIS cells (Fig. 1E), and overexpression efficiency of SLU7 in parental T24 and UMUC3 cells (Fig. 1F). Functionally, stable SLU7 knockdown significantly reduced cisplatin IC₅₀ values in T24-CIS and UMUC3-CIS cells, reversing the resistant phenotype (Figs. 1G and 1H). Conversely, SLU7 overexpression in parental T24 and UMUC3 cells both enhanced cisplatin resistance (Figs. 1I and 1J). These results collectively confirm that SLU7 is a key driver of cisplatin resistance in BLCA, and its pro-resistance function is conserved across different BLCA cell lines, which is consistent with our clinical cohort findings. SLU7 mediates cisplatin resistance by specifically activating the p38 MAPK pathway To elucidate the molecular mechanism underlying SLU7-mediated cisplatin resistance, we performed RNA-seq and GO enrichment analysis on SLU7-knockdown T24-CIS cells. The results showed that SLU7 depletion significantly downregulated the signaling activity of the MAP3K family (Fig. 2A). Detailed expression changes of individual MAP3K family member are listed in Supplementary Table S4. These finding point to the MAPK pathway as a potential downstream target.Fig. 2SLU7 promotes cisplatin resistance by activating the p38 MAPK pathway. (A) GO pathway enrichment analysis of RNA-seq data from SLU7-knockdown T24-CIS cells, highlighting downregulated MAP3K family signaling pathways. (B) Western blotting analysis of phosphorylation levels of ERK1/2, p38 MAPK, JNK/SAPK, and ERK5 in T24-CIS, UMUC3-CIS, and UMUC3 cells with SLU7 knockdown or overexpression. (C, E) Western blotting analysis of p38 and p-p38 protein levels in SLU7-overexpressing T24 (C) and UMUC3 (E) cells treated with the p38 inhibitor Adezmapimod. (D, F) CCK-8 assays showing cisplatin IC₅₀ values in SLU7-overexpressing T24 (D) and UMUC3 (F) cells treated with Adezmapimod. Data are presented as mean ± SD. p-values were calculated using one-way ANOVA. ***p < 0.001, ****p < 0.0001, ns indicates no significant difference SLU7 promotes cisplatin resistance by activating the p38 MAPK pathway. (A) GO pathway enrichment analysis of RNA-seq data from SLU7-knockdown T24-CIS cells, highlighting downregulated MAP3K family signaling pathways. (B) Western blotting analysis of phosphorylation levels of ERK1/2, p38 MAPK, JNK/SAPK, and ERK5 in T24-CIS, UMUC3-CIS, and UMUC3 cells with SLU7 knockdown or overexpression. (C, E) Western blotting analysis of p38 and p-p38 protein levels in SLU7-overexpressing T24 (C) and UMUC3 (E) cells treated with the p38 inhibitor Adezmapimod. (D, F) CCK-8 assays showing cisplatin IC₅₀ values in SLU7-overexpressing T24 (D) and UMUC3 (F) cells treated with Adezmapimod. Data are presented as mean ± SD. p-values were calculated using one-way ANOVA. ***p < 0.001, ****p < 0.0001, ns indicates no significant difference We further examined the phosphorylation status of core MAPK subtypes (ERK1/2, p38 MAPK, JNK/SAPK, and ERK5) in SLU7-altered cells. Western blotting demonstrated that SLU7 knockdown specifically reduced the phosphorylation of p38 MAPK (p-p38) in T24-CIS and UMUC3-CIS cells, while SLU7 overexpression in UMUC3 cells upregulated p-p38 levels. No significant changes were observed in the phosphorylation of ERK1/2, JNK/SAPK, or ERK5 (Fig. 2B), indicating SLU7 specifically targets the p38 MAPK pathway. To verify the causal relationship, we used Adezmapimod, a highly specific p38 MAPK inhibitor that competitively binds the ATP pocket to block p38 catalytic activity [20]. In T24 cells, Adezmapimod pretreatment blocked SLU7-induced p38 activation (Fig. 2C) and reversed the cisplatin-resistant phenotype in SLU7-overexpressing T24 (Fig. 2D); in UMUC3 cells, it similarly abrogated SLU7-mediated p38 activation (Fig. 2E) and reversed enhanced cisplatin resistance (Fig. 2F). These data confirm that SLU7 mediates cisplatin resistance through specific activation of the p38 MAPK pathway. SLU7 activates the p38 MAPK pathway through MAP3K3 protein upregulation To identify the MAP3K subtype linking SLU7 to p38 activation, we screened MAP3K family members in clinical cohorts and found MAP3K3 expression correlated with cisplatin resistance (Supplement Figs. 2A–C). Functional validation showed that MAP3K3 knockdown in T24-CIS and UMUC3-CIS cells reduced p-p38 levels and reversed cisplatin resistance (Supplement Figs. 2D–F), while MAP3K3 overexpression enhanced cisplatin resistance in UMUC3 cells (Supplement Fig. 2G). We next explored the regulatory relationship between SLU7 and MAP3K3. Western blotting revealed that SLU7 knockdown significantly downregulated MAP3K3 protein levels, while SLU7 overexpression upregulated them (Fig. 3A). Although SLU7 alternation was associated with MAP3K3 mRNA levels, qRT-PCR showed that such changes were relatively small (Figs. 3B–D), indicating post-transcriptional regulation—consistent with the RBP property of SLU7.Fig. 3SLU7 upregulates MAP3K3 to activate the p38 MAPK pathway. (A) Western blotting analysis of MAP3K3 protein expression in T24-CIS, UMUC3-CIS, and UMUC3 cells with SLU7 knockdown or overexpression. (B–D) qRT-PCR analysis of MAP3K3 mRNA levels in T24-CIS (B), UMUC3-CIS (C), and UMUC3 (D) cells with SLU7 knockdown or overexpression. (E, G) Western blotting analysis of SLU7, MAP3K3, p38, and p-p38 protein levels in SLU7-overexpressing T24 (E) and UMUC3 (G) cells with MAP3K3 knockdown. (F, H) CCK-8 assays showing cisplatin IC₅₀ values in SLU7-overexpressing T24 (F) and UMUC3 (H) cells with MAP3K3 knockdown. Data are presented as mean ± SD. p-values were calculated using unpaired two-tailed Student’s t-test or one-way ANOVA. **p < 0.01, ***p < 0.001, ****p < 0.0001, ns indicates no significant difference SLU7 upregulates MAP3K3 to activate the p38 MAPK pathway. (A) Western blotting analysis of MAP3K3 protein expression in T24-CIS, UMUC3-CIS, and UMUC3 cells with SLU7 knockdown or overexpression. (B–D) qRT-PCR analysis of MAP3K3 mRNA levels in T24-CIS (B), UMUC3-CIS (C), and UMUC3 (D) cells with SLU7 knockdown or overexpression. (E, G) Western blotting analysis of SLU7, MAP3K3, p38, and p-p38 protein levels in SLU7-overexpressing T24 (E) and UMUC3 (G) cells with MAP3K3 knockdown. (F, H) CCK-8 assays showing cisplatin IC₅₀ values in SLU7-overexpressing T24 (F) and UMUC3 (H) cells with MAP3K3 knockdown. Data are presented as mean ± SD. p-values were calculated using unpaired two-tailed Student’s t-test or one-way ANOVA. **p < 0.01, ***p < 0.001, ****p < 0.0001, ns indicates no significant difference Rescue experiments confirmed that in T24 cells, MAP3K3 knockdown blocked SLU7-induced p38 activation (Fig. 3E) and abrogated SLU7-mediated cisplatin resistance (Fig. 3F). Consistently, in UMUC3 cells, MAP3K3 knockdown abrogated SLU7-induced p38 activation (Fig. 3G) and reversed SLU7-mediated cisplatin resistance (Fig. 3H). These results demonstrate that SLU7 upregulates MAP3K3 protein expression to activate the p38 MAPK pathway, contributing to cisplatin resistance. SLU7 regulates MAP3K3 by mediating its mRNA nuclear export, a non-canonical role independent of splicing Given SLU7’s canonical role as a splicing factor and its RBP property, we hypothesized two potential mechanisms: alternative splicing or direct mRNA binding. RIP-qPCR confirmed specific binding between SLU7 and MAP3K3 mRNA in UMUC3 cells (Fig. 4A), and IF-smiFISH showed co-localization of SLU7 and MAP3K3 mRNA in both nucleus and cytoplasm (Figs. 4B and C).Fig. 4SLU7 mediates MAP3K3 mRNA nuclear export to regulate its expression. (A) RIP-qPCR analysis showing the interaction between SLU7 and MAP3K3 mRNA in UMUC3–SLU7-Flag cells. (B, C) The location of SLU7 and MAP3K3 mRNA in UMUC3 cells were analyzed using IF and smiFISH. Scale bar: 10 μm. The fluorescence intensity curves of DAPI (blue), SLU7 (green) and MAP3K3 mRNA (purple) that crossed the arrows were analyzed. (D, E) qRT-PCR analysis of MAP3K3 mRNA levels in nuclear and cytoplasmic fractions of T24-CIS (D) and UMUC3-CIS (E) cells with SLU7 knockdown. (F, G) RNA-FISH images showing subcellular localization of MAP3K3 mRNA (purple) in T24-CIS (F) and UMUC3-CIS (G) cells with SLU7 knockdown. Scale bar: 10 μm. Data are presented as mean ± SD. p-values were calculated using unpaired two-tailed Student’s t-test or one-way ANOVA. ****p < 0.0001, ns indicates no significant difference SLU7 mediates MAP3K3 mRNA nuclear export to regulate its expression. (A) RIP-qPCR analysis showing the interaction between SLU7 and MAP3K3 mRNA in UMUC3–SLU7-Flag cells. (B, C) The location of SLU7 and MAP3K3 mRNA in UMUC3 cells were analyzed using IF and smiFISH. Scale bar: 10 μm. The fluorescence intensity curves of DAPI (blue), SLU7 (green) and MAP3K3 mRNA (purple) that crossed the arrows were analyzed. (D, E) qRT-PCR analysis of MAP3K3 mRNA levels in nuclear and cytoplasmic fractions of T24-CIS (D) and UMUC3-CIS (E) cells with SLU7 knockdown. (F, G) RNA-FISH images showing subcellular localization of MAP3K3 mRNA (purple) in T24-CIS (F) and UMUC3-CIS (G) cells with SLU7 knockdown. Scale bar: 10 μm. Data are presented as mean ± SD. p-values were calculated using unpaired two-tailed Student’s t-test or one-way ANOVA. ****p < 0.0001, ns indicates no significant difference To rule out splicing-dependent regulation, we knocked down PRPF8 and CWC22—key components of the SLU7-associated splicing complex [21]. Western blotting and qRT-PCR showed no significant changes in MAP3K3 protein or mRNA levels (Supplementary Figures 3A–H), and RIP-qPCR confirmed PRPF8/CWC22 did not bind MAP3K3 mRNA (Supplementary Figures 3I and J). These data exclude SLU7’s canonical splicing function in regulating MAP3K3. We then tested the hypothesis of mRNA nuclear export regulation. Nucleocytoplasmic fractionation and qRT-PCR showed that SLU7 knockdown significantly reduced cytoplasmic MAP3K3 mRNA levels without affecting nuclear levels (Figs. 4D and E). RNA-FISH further confirmed MAP3K3 mRNA retention in the nucleus of SLU7-depleted T24-CIS and UMUC3-CIS cells (Figs. 4F and G). These results uncover a novel non-canonical function of SLU7: mediating MAP3K3 mRNA nuclear export to regulate its translation. NAA50 maintains SLU7 protein stability via N-terminal acetylation To explore upstream regulators of SLU7, we focused on post-translational modifications (PTMs) that regulate RBP stability. Mass spectrometry identified N-terminal acetylation of SLU7 (Fig. 5A)—a PTM known to prevent ubiquitin-proteasome degradation [22].Fig. 5NAA50 maintains SLU7 protein stability via N-terminal acetylation. (A) MS analysis identifying N-terminal acetylation of SLU7. (B) Western blotting analysis of SLU7 protein expression in T24-CIS cells with knockdown of different NAT subtypes. (C) Western blotting analysis of SLU7, MAP3K3, p38, and p-p38 protein levels in T24-CIS, UMUC3-CIS, and UMUC3 cells with NAA50 knockdown or overexpression. (D) Western blotting analysis of SLU7, MAP3K3, p38, and p-p38 protein levels in T24-CIS and UMUC3-CIS cells treated with the specific NAA50 inhibitor Naa50-IN-1. (E) Western blotting analysis verifying that SLU7 knockdown abrogates the regulation effect of NAA50 on MAP3K3 and p38 phosphorylation in T24-CIS cells. (F) Cycloheximide chase assay detecting the time-dependent of SLU7 protein stability in UMUC3 cells with NAA50 knockdown (siNAA50) or NAA50 inhibitor (Naa50-IN-1) treatment, compared with their respective control groups(siNC or DMSO). (G and H) IP assays detecting SLU7^S2ac (N-terminal acetylation) levels in UMUC3 cells with NAA50 knockdown (G) or Naa50-IN-1 treatment (H) in the presence of the proteasome inhibitor MG132 pretreatment. (I) Western blotting analysis of SLU7 protein stability in UMUC3 cells expressing Flag-tagged SLU7 wild-type (SLU7WT-Flag) or acetylation site-mutant (SLU7MUT-Flag) constructs upon Naa50-IN-1 treatment with CHX pretreatment. (J) Ubiquitination assay in 293T cells overexpressing Flag-tagged SLU7, detecting SLU7 ubiquitination level upon Naa50-IN-1 treatment NAA50 maintains SLU7 protein stability via N-terminal acetylation. (A) MS analysis identifying N-terminal acetylation of SLU7. (B) Western blotting analysis of SLU7 protein expression in T24-CIS cells with knockdown of different NAT subtypes. (C) Western blotting analysis of SLU7, MAP3K3, p38, and p-p38 protein levels in T24-CIS, UMUC3-CIS, and UMUC3 cells with NAA50 knockdown or overexpression. (D) Western blotting analysis of SLU7, MAP3K3, p38, and p-p38 protein levels in T24-CIS and UMUC3-CIS cells treated with the specific NAA50 inhibitor Naa50-IN-1. (E) Western blotting analysis verifying that SLU7 knockdown abrogates the regulation effect of NAA50 on MAP3K3 and p38 phosphorylation in T24-CIS cells. (F) Cycloheximide chase assay detecting the time-dependent of SLU7 protein stability in UMUC3 cells with NAA50 knockdown (siNAA50) or NAA50 inhibitor (Naa50-IN-1) treatment, compared with their respective control groups(siNC or DMSO). (G and H) IP assays detecting SLU7^S2ac (N-terminal acetylation) levels in UMUC3 cells with NAA50 knockdown (G) or Naa50-IN-1 treatment (H) in the presence of the proteasome inhibitor MG132 pretreatment. (I) Western blotting analysis of SLU7 protein stability in UMUC3 cells expressing Flag-tagged SLU7 wild-type (SLU7WT-Flag) or acetylation site-mutant (SLU7MUT-Flag) constructs upon Naa50-IN-1 treatment with CHX pretreatment. (J) Ubiquitination assay in 293T cells overexpressing Flag-tagged SLU7, detecting SLU7 ubiquitination level upon Naa50-IN-1 treatment N-terminal acetylation is an irreversible modification catalyzed by N-terminal acetyltransferases (NATs). Unlike lysine acetylation, N-terminal acetylation maintains structural stability by transferring an acetyl group to the N-terminus of the protein, and proteins lacking this modification are prone to degradation by the ubiquitin-proteasome system. Screening of NAT family members showed only NAA50 knockdown significantly downregulated SLU7 protein levels in T24-CIS cells (Figs. 5B and Supplementary Figure 4A). NAA50 knockdown reduced SLU7, MAP3K3, and p-p38 protein levels, while NAA50 overexpression upregulated these molecules (Fig. 5C). Treatment with Naa50-IN-1 (a specific NAA50 inhibitor, which acts by competitively binding to the AcCoA-binding pocket of NAA50 to block its N-terminal acetylation activity [23]) recapitulated these effects in T24-CIS and UMUC3-CIS cells (Fig. 5D). To further validate that the regulatory effects of NAA50 are SLU7-dependent, we performed rescue assays and confirmed that SLU7 knockdown abrogated NAA50-mediated regulation of MAP3K3 expression and p38 phosphorylation in T24-CIS cells (Fig. 5E). These results collectively confirm that NAA50 drives the activation of the MAP3K3-p38 MAPK signaling pathway through SLU7. To further dissect the mechanism of NAA50-mediated SLU7 regulation, we performed cycloheximide (CHX) chase assays. The results demonstrated that both NAA50 knockdown and pharmacological inhibition with Naa50-IN-1 markedly impaired SLU7 stability in UMUC3 cells (Fig. 5F), collectively verifying that NAA50 is indispensable for maintaining SLU7 stability. Next, we generated the SLU7^S2ac antibody and performed IP assays. Specifically, IP results confirmed NAA50 knockdown or Naa50-IN-1 treatment reduced SLU7 N-terminal acetylation levels, and pretreatment with the proteasome inhibitor MG132 abrogated SLU7 degradation (Figs. 5G and H). To further definitively verify that NAA50-mediated N-terminal acetylation is the primary mechanism maintaining SLU7 protein stability, we conducted stability assays of SLU7 wild-type (SLU7WT-Flag) and acetylation site-mutant (SLU7MUT-Flag) constructs in the presence of CHX and Naa50-IN-1. Naa50-IN-1 treatment markedly decreased the protein level of SLU7WT-Flag, whereas the stability of SLU7MUT-Flag was not significantly affected by Naa50-IN-1 intervention (Fig. 5I). These results conclusively demonstrate that NAA50 maintains SLU7 protein stability in an acetylation-dependent manner, and that N-terminal acetylation of SLU7 is the key post-translational modification mediating this regulatory effect of NAA50. We further performed ubiquitination assays in 293T cells with Flag-tagged SLU7 overexpressed, and the results showed that treatment with Naa50-IN-1 significantly enhanced the ubiquitination level of SLU7 (Fig. 5J). Collectively, these findings conclusively demonstrate that NAA50 maintains SLU7 protein stability in an acetylation-dependent manner. Mechanistically, NAA50 mediates the N-terminal acetylation of SLU7 to inhibit its ubiquitination and subsequent proteasomal degradation, whereas Naa50-IN-1 mediated inhibition of NAA50 impairs SLU7 N-terminal acetylation, thereby promoting SLU7 ubiquitination and accelerating its proteasomal degradation. These results further support that NAA50 maintains SLU7 stability by catalyzing its N-terminal acetylation, thus sustaining downstream activation of the MAP3K3-p38 MAPK pathway. Targeting NAA50 reverses cisplatin resistance in vitro and in vivo To validate the therapeutic potential of the NAA50–SLU7–MAP3K3-p38 axis, we treated cisplatin-resistant cells with Naa50-IN-1. CCK-8 assays showed Naa50-IN-1 significantly reduced cisplatin IC₅₀ values in T24-CIS and UMUC3-CIS cells, restoring cisplatin sensitivity (Figs. 6A and B).Fig. 6NAA50 inhibition reverses cisplatin resistance in vitro and in vivo. (A, B) CCK-8 assays showing cisplatin IC₅₀ values in T24-CIS (A) and UMUC3-CIS (B) cells treated with Naa50-IN-1. (C) Representative images of subcutaneous tumors from nude mice in each treatment group. Scale bar, 1 cm. (D) Tumor volume growth curves in nude mice. (E, F) Final tumor volume (E) and weight (F) in nude mice. Data are presented as mean ± SD (n = 6 per group). p-values were calculated using unpaired two-tailed Student’s t-test, one-way ANOVA, or two-way ANOVA. ****p < 0.0001 NAA50 inhibition reverses cisplatin resistance in vitro and in vivo. (A, B) CCK-8 assays showing cisplatin IC₅₀ values in T24-CIS (A) and UMUC3-CIS (B) cells treated with Naa50-IN-1. (C) Representative images of subcutaneous tumors from nude mice in each treatment group. Scale bar, 1 cm. (D) Tumor volume growth curves in nude mice. (E, F) Final tumor volume (E) and weight (F) in nude mice. Data are presented as mean ± SD (n = 6 per group). p-values were calculated using unpaired two-tailed Student’s t-test, one-way ANOVA, or two-way ANOVA. ****p < 0.0001 Subcutaneous xenograft models (T24-CIS cells) showed monotherapy with cisplatin or Naa50-IN-1 slowed tumor growth, but the combination exhibited the strongest inhibitory effect. Tumor weight and volume were significantly lower in the combination group, confirming in vivo efficacy (Figs. 6C–6F). These results validate NAA50 as a promising therapeutic target for reversing cisplatin resistance in BLCA. Discussion Cisplatin-based chemotherapy remains the backbone of MIBC treatment, but cisplatin resistance remains as a major barrier to improved survival [24, 25]. This study identifies a novel “NAA50‑SLU7‑MAP3K3‑p38 MAPK” regulatory axis that mediates cisplatin resistance in BLCA, thereby filling an important gap in the understanding of RBP‑driven chemoresistance. Our findings further reveal noncanonical functions of SLU7 and establish NAA50 as a promising therapeutic target, consistent with the unmet clinical need emphasized in the introduction (Fig. 7).Fig. 7Schematic diagram of the “NAA50–SLU7–MAP3K3-p38 MAPK” regulatory axis in cisplatin resistance. NAA50 catalyzes N-terminal acetylation of SLU7 to maintain its protein stability. Stabilized SLU7 directly binds to MAP3K3 mRNA, promoting its nuclear export and translation. Increased MAP3K3 protein activates the p38 MAPK pathway, leading to cisplatin resistance in BLCA. Targeting NAA50 with Naa50-IN-1 downregulates SLU7 expression, inhibits the MAP3K3-p38 MAPK pathway, and restores cisplatin sensitivity Schematic diagram of the “NAA50–SLU7–MAP3K3-p38 MAPK” regulatory axis in cisplatin resistance. NAA50 catalyzes N-terminal acetylation of SLU7 to maintain its protein stability. Stabilized SLU7 directly binds to MAP3K3 mRNA, promoting its nuclear export and translation. Increased MAP3K3 protein activates the p38 MAPK pathway, leading to cisplatin resistance in BLCA. Targeting NAA50 with Naa50-IN-1 downregulates SLU7 expression, inhibits the MAP3K3-p38 MAPK pathway, and restores cisplatin sensitivity Our clinical cohort analysis demonstrates that high SLU7 expression correlates with poor CSS and RFS in cisplatin-treated BLCA patients. This finding positions SLU7 as a potential predictive biomarker for cisplatin response, filling the unmet need for reliable markers to stratify patients likely to benefit from cisplatin-based therapy. Unlike previously reported RBPs (e.g., IGF2BP3, NAT10 [11, 12]), SLU7 integrates both immune escape (our prior work [17]) and cisplatin resistance, making it a dual-function oncogenic RBP in BLCA. This dual role suggests SLU7-high patients may benefit from combined targeting of SLU7 and immune checkpoint inhibitors, a direction worthy of future clinical exploration. SLU7 was traditionally recognized as a splicing factor involved in genome integrity and cell cycle regulation [26]. Our prior study uncovered its role in promoting immune escape via PI3K/Akt activation [17], and here we further identify a novel non-canonical function: mediating MAP3K3 mRNA nuclear export to enhance cisplatin resistance. This expands the functional diversity of SLU7 beyond splicing and translation regulation, highlighting RBPs’ ability to exert pleiotropic effects via distinct post-transcriptional mechanisms. Notably, SLU7’s regulation of MAP3K3 is independent of its own splicing complex partners (PRPF8/CWC22), emphasizing the specificity of this non-canonical pathway. This finding adds to the growing evidence that RBPs can switch between canonical and non-canonical functions in a context-dependent manner—an important consideration for targeting RBPs in cancer. Given that SLU7 is defined as an RNA-binding protein, the significant correlation between SLU7 alteration and MAP3K3 mRNA levels observed in our study warrants further discussion of potential post-transcriptional mechanisms. Importantly, our results demonstrate that SLU7 interacts with MAP3K3 mRNA in both the nucleus and cytoplasm, supporting the notion that SLU7 regulates MAP3K3 expression at least in part by promoting its nuclear export. Beyond mRNA nuclear export, SLU7 could potentially modulate MAP3K3 expression by affecting mRNA stability, splicing efficiency, or translational regulation, all of which are canonical functions exerted by RNA-binding proteins [14]. Regarding the specific mechanism by which SLU7 facilitates MAP3K3 mRNA nuclear exports, our unbiased mass spectrometry analysis of endogenous SLU7-interacting proteins did not identify canonical mRNA export factors such as NXF1 or NXT1, suggesting that SLU7 may regulate MAP3K3 mRNA nuclear export through a non-canonical or currently uncharacterized export machinery. Future studies will be needed to identify the specific adaptor or transporter that mediate the selective nuclear export of MAP3K3 mRNA by SLU7. The MAPK pathway is a well-established driver of cisplatin resistance in BLCA [27, 28], but upstream regulators linking RBPs to MAPK activation remain poorly defined. Our study identifies MAP3K3 as the key MAP3K subtype mediating SLU7-induced p38 activation, distinguishing it from other MAPK branches (ERK1/2, JNK, ERK5) that are not affected by SLU7. This specificity underscores the precision of the regulatory axis and reduces the risk of off-target effects when targeting this pathway. Furthermore, we are the first to report NAA50 as an upstream regulator of SLU7 stability via N-terminal acetylation. N-terminal acetylation is an evolutionarily conserved and irreversible protein modification that is widely known to govern protein stability, folding, and resistance to ubiquitindependent proteasomal degradation, representing a regulatory mode distinct from classical lysine acetylation [29]. Mounting evidence has demonstrated that N-terminal acetylation mediated by N-terminal acetyltransferase (NAT) family members can shield substrate proteins from N-degron pathway recognition and subsequent proteolysis, thereby extending protein half-life [30, 31]. Our data confirm that NAA50-mediated N-terminal acetylation prevents SLU7 degradation by the ubiquitin-proteasome system. This mechanism is distinct from other PTM-mediated RBP regulation (e.g., phosphorylation, methylation), providing a new paradigm for targeting RBP stability in cancer. Of note, NAA50 belongs to the NAT family, which also includes prominent members such as NAA10 and NAA20. In contrast to NAA10 and NAA20, which mainly catalyze global co-translational N-terminal acetylation for general proteome homeostasis, NAA50 displays narrower and more selective substrate specificity [32]. Although other NAT family members have been implicated in various cancers, their functions in BLCA cisplatin resistance remain largely unclear. In the present study, we identified NAA50 as a specific upstream regulator that acetylates and stabilizes SLU7, a function distinct from the global acetylation events mediated by canonical NATs. This substrate selectivity highlights the unique and non-redundant role of NAA50 within the NAT family in driving the SLU7–MAP3K3-p38 MAPK signaling axis and cisplatin resistance in BLCA. Prior studies have shown that RBPs mediate cisplatin resistance via mRNA stability (HKDC1 [7]) or DNA repair (NAT10 [12]). Our work complements these findings by identifying mRNA nuclear export as a novel post-transcriptional mechanism underlying cisplatin resistance. Additionally, while MAP3K3 has been implicated in other cancers [33, 34], its role in BLCA cisplatin resistance and regulation by SLU7–NAA50 is newly discovered. The validation of Naa50-IN-1 in reversing cisplatin resistance in vitro and in vivo is a critical translational advance. Unlike direct SLU7 inhibitors (which are currently unavailable), Naa50-IN-1 is a small-molecule inhibitor with established bioavailability, making it a viable candidate for repurposing in BLCA combination therapy. This addresses the urgent need for targeted agents to overcome cisplatin resistance. In summary, this study uncovers a novel regulatory axis mediating cisplatin resistance in BLCA, delineates non-canonical functions of SLU7, and validates NAA50 as a therapeutic target. The findings not only advance our understanding of post-transcriptional regulation in chemoresistance but also provide a rationale for developing combination therapies with Naa50-IN-1 to improve cisplatin efficacy in BLCA patients. This work addresses the critical clinical need for predictive biomarkers and targeted strategies to overcome cisplatin resistance, paving the way for personalized treatment of BLCA. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3